Simulations Plus (SLP) Hisse Fiyat
Simulations Plus Fiyat
Simulations Plus, son 19 yılda gelirini yıllık %14,7 artırarak 79,18 M USD seviyesine taşıdı. Hisse başına kâr, son 18 yılda yıllık %15,0 büyüdü. Simulations Plus için net marj, %-81,7 ile birkaç yıl önceki %21,1 seviyesine göre geriledi. Bugünkü fiyata göre temettü verimi kabaca %0,97 seviyesine denk geliyor. Temettü dağıtım oranı, kârın yaklaşık %37 düzeyindedir. Simulations Plus için 12 aylık konsensüs fiyat hedefi 18,50 USD; bu, hissenin bugünkü fiyatının yaklaşık %0,0 üzerinde bir seviyeye denk geliyor. 12 analistten 0 tanesi hisse için alım öneriyor — genel konsensüs: Sat.
Simulations Plus hisse senedi fiyatı
Simulations Plus iş modeli ve hisse analizi
Simulations Plus hakkında sık sorulan sorular
Simulations Plus Inc is primarily active in the pharmaceutical and biotechnology industries. With a focus on simulation software and consulting services, the company provides cutting-edge solutions for drug discovery and development. Simulations Plus Inc's expertise in modeling and simulation technologies helps pharmaceutical companies optimize their drug formulation and dosage strategies. By leveraging their industry-leading software platforms, Simulations Plus Inc supports the efficient research and development of new therapies, enhancing the overall success and effectiveness of pharmaceutical companies.
The main competitors of Simulations Plus Inc in the market include Certara, Inc and Dassault Systèmes.
The business model of Simulations Plus Inc revolves around providing software and consulting services for pharmaceutical research and development. As a leading provider in the field of drug discovery and development, Simulations Plus Inc aims to enhance the efficiency and effectiveness of the pharmaceutical industry through their innovative solutions. By utilizing computer modeling and simulation software, the company assists in predicting and optimizing drug properties, interactions, and outcomes. This enables scientists and researchers to make informed decisions throughout the drug development process, leading to improved efficacy, safety, and reduced costs. Simulations Plus Inc's comprehensive solutions cater to the needs of pharmaceutical companies, regulatory agencies, and academia worldwide.
Simulations Plus Inc is a leading provider of simulation and modeling software for the pharmaceutical and biotechnology industries. Established in 1996, the company has amassed extensive expertise in the field. Simulations Plus Inc has developed a strong reputation for its cutting-edge technology and innovative solutions, helping pharmaceutical companies optimize drug discovery and development processes. With a focus on increasing efficiency and reducing costs, Simulations Plus Inc has become a trusted partner for numerous organizations worldwide. The company's commitment to excellence has earned them recognition and a loyal customer base. Simulations Plus Inc continues to drive advancements in the industry, delivering impactful software solutions that streamline drug development.
Simulations Plus Inc has achieved significant milestones throughout its history. Some notable accomplishments include the development and release of their industry-leading software solutions, such as GastroPlus™ and DDDPlus™, which have gained widespread recognition and adoption in the pharmaceutical industry. The company has also formed strategic partnerships and collaborations with top pharmaceutical companies, further establishing its presence and credibility in the market. Additionally, Simulations Plus Inc has a strong track record of achieving consistent revenue growth and delivering value to its shareholders. These achievements reflect the company's commitment to innovation, excellence, and meeting the evolving needs of the life sciences industry.
Simulations Plus Inc is primarily present in the United States.
Simulations Plus Inc represents values of innovation, scientific excellence, and customer satisfaction. With a corporate philosophy focused on advancing pharmaceutical research and enhancing drug development, Simulations Plus Inc strives to provide cutting-edge software and consulting services. By combining advanced technologies and domain knowledge, the company facilitates cost-effective and efficient drug discovery and development processes. Simulations Plus Inc is committed to delivering high-quality solutions, fostering collaborative relationships, and continuously improving its products and services.
Analistler şu anda Simulations Plus hissesi için ortalama 18,50 USD hedef fiyat belirliyor (medyan: 18,50 USD); bu, son fiyata göre +0,0 % anlamına gelir. Konsensüs 12 analist notuna dayanır.
12 analist şu anda Simulations Plus hissesini değerlendiriyor: 0 al, 7 tut, 5 sat öneriyor. 2026 için analistler Simulations Plus şirketinin 81,95 M USD gelir ve 0,86 USD hisse başına kâr üretmesini bekliyor.
Güncel döviz kuruyla Simulations Plus hissesi 16,51 EUR (18,50 USD) seviyesindedir.
Simulations Plus hissesi (SLP) 1 borsada işlem görür, bunlar arasında: NASDAQ (SLP).
Simulations Plus Inc. is a leading company in the field of simulation technology and software development. It provides solutions for researchers and experts in various industries, including biotechnology, pharmaceuticals, agriculture, food technology, and more. The company offers a range of products and tools for data analysis and innovative strategy development to bring new products and applications to the market. Some of its notable products include PK-SIM, MoBi, ADMET Predictor, GastroPlus, DILIsym, and MedChem Studio. Simulations Plus also offers solutions for the agricultural sector, such as Cartagenia, Crop Laptop, and Dose Response Toxicology. The company provides training and support to its customers, aiming to optimize their business processes. Its business model focuses on processing and analyzing large data sets to provide relevant insights and support decision-making processes. Simulations Plus aims to expand into new markets and develop products based on the latest technological advancements.
beklenen'nin Simulations Plus hasılatı 81,95 M USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin Simulations Plus karı 17,49 M USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Simulations Plus'nin Fiyat/Kazanç (F/K) oranı şu anda 21,39'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Simulations Plus hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Simulations Plus'nin Fiyat/Satış (F/S) oranı şu anda 4,56'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Simulations Plus hisse senedinin değerleme metriği olarak hizmet eder.
Simulations Plus'nin Eulerpool Kalite Puanı 3/10'dur.
Simulations Plus'nin ISIN'i US8292141053'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Simulations Plus'nin WKN'i 924294'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Simulations Plus'nin ticker'ı SLP'dir. Ticker sembolü, Simulations Plus hisseleri borsada işlem görmek için kullanılır.
Simulations Plus Hissesi
Simulations Plus Emsaller Grubu
Simulations Plus Ticker
Simulations Plus FIGI
Simulations Plus'nin tüm temel göstergeleri ve derinlemesine analizi
Simulations Plus hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Simulations Plus şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: